Sonic Healthcare Stock
€15.99
Your prediction
Sonic Healthcare Stock
Pros and Cons of Sonic Healthcare in the next few years
Pros
Cons
Performance of Sonic Healthcare vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Sonic Healthcare | 0.010% | -3.302% | 6.260% | -26.177% | -18.168% | -33.026% | -5.385% |
Ansell Ltd. | -1.240% | -0.617% | 8.054% | 2.417% | 5.574% | -37.910% | 2.222% |
Cochlear Ltd | -0.510% | -3.665% | -1.621% | 40.323% | 8.343% | 27.032% | 51.246% |
Bio-Rad Labs Inc. A | 0.850% | -4.853% | -4.415% | -28.325% | -15.191% | -55.929% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Overall, Sonic Healthcare seems to be in relatively good financial health based on the provided financial statements. From a general perspective, the company showcases strong growth in its revenue, considerable increase in net income and a solid balance sheet, which can bode well for its prospects. However, as with any business, there are both positives and negatives to consider when evaluating its financial performance.
Revenue growth: The income statements demonstrate a consistent growth in total revenue year-over-year, from AUD 6.83 billion in 2020 to AUD 8.75 billion in 2021 and reaching AUD 9.34 billion in 2022. This is an encouraging sign that Sonic Healthcare continues to expand and leverage its position within the Healthcare Providers & Services industry.
Net income improvement: Net income has seen a notable upward trend, increasing from AUD 527.7 million in 2020 to AUD 1.46 billion in 2022. This indicates that the company has managed to boost its profitability and efficiently control costs.